Cover Image
市場調查報告書

藥物輸送相關各種合作契約:交易趨勢,企業及財務狀況

Global Drug Delivery Partnering 2010-2016: Deal Trends, Players and Financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 254756
出版日期 內容資訊 英文 1,000+ Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物輸送相關各種合作契約:交易趨勢,企業及財務狀況 Global Drug Delivery Partnering 2010-2016: Deal Trends, Players and Financials
出版日期: 2016年11月18日 內容資訊: 英文 1,000+ Pages
簡介

本報告提供藥物輸送相關之各種合作契約調查分析,彙整近幾年的各種契約趨勢,大規模契約及大醫藥品經營者的契約概要,契約區分·開發階段·治療領域·各技術類型一覽等資料。

摘要整理

第1章 簡介

第2章 藥物輸送相關各種契約動向

  • 簡介
  • 過去數年的藥物輸送相關合作
  • 對藥物輸送最積極的大型製藥公司
  • 藥物輸送相關合作:各類型契約
  • 藥物輸送相關合作:各治療領域
  • 藥物輸送相關合作所明確開出的金融條件
    • 交易總額
    • 預付款付款額
    • 目標達成褒獎金
    • 權利金比率

第3章 主要契約

  • 簡介
  • 主要契約:各交易金額

第4章 對藥物輸送最積極的交易企業

  • 簡介
  • 對藥物輸送最積極的交易企業
  • 對藥物輸送最積極的合作企業簡介

第5章 藥物輸送契約交易一覽

  • 簡介
  • 藥物輸送契約交易一覽

第6章 藥物輸送契約:各技術類型

第7章 合作資源中心

  • 線上合作
  • 合作趨勢
  • 相關資料

附錄

  • 附錄1:藥物輸送契約(各企業A-Z)
  • 附錄2:藥物輸送契約(各開發階段)
    • 藥物研發
    • 前臨床
    • 階段Ⅰ
    • 階段Ⅱ
    • 階段Ⅲ
    • 法規
    • 上市
    • 處方
  • 附錄3:藥物輸送契約(各類型)
    • 資產購買
    • 轉讓
    • 大型製藥公司的對外授權
    • 共同開發
    • 共同R&D
    • 共同上市
    • 共同促銷
    • CRADA
    • 交叉授權
    • 開發
    • 流通銷售
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業
    • 授權
    • 訴訟
    • 製造
    • 行銷
    • 物質移動
    • 選擇
    • 推銷
    • 研究
    • 協定
    • 衍生公司
    • 輔助許可證
    • 供給
    • 技術轉移
    • 契約解除
    • 保證
  • 附錄4:藥物輸送契約(各治療領域)
  • 附錄5:契約類型定義

關於Wildwood Ventures

Current Partnering Current Agreements CurrentPartnering的發行標題

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2102

The ‘Global Drug Delivery Partnering 2010-2016 ’ report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1,800 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits

‘Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts ’ provides the reader with the following key benefits:

  • In-depth understanding of Drug Delivery deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Drug Delivery agreements with numerous real life case studies
  • Detailed access to actual Drug Delivery contracts entered into by leading biopharma companies
  • Identify most active Drug Delivery dealmakers since 2010
  • Insight into terms included in a Drug Delivery partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts ’ is intended to provide the reader with an in-depth understanding and access to Drug Delivery trends and structure of deals entered into by leading companies worldwide.

‘Drug Delivery Partnering Terms and Agreements ’ includes:

  • Trends in Drug Delivery dealmaking in the biopharma industry since 2010
  • Analysis of Drug Delivery deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Drug Delivery deals
  • Access to Drug Delivery contract documents
  • Leading Drug Delivery deals by value since 2010
  • Most active Drug Delivery dealmakers since 2010

In ‘Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts ’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts ’ report provides comprehensive access to available deals and contract documents for over 1,800 Drug Delivery deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Drug Delivery dealmaking

  • 2.1. Introduction
  • 2.2. Drug Delivery partnering over the years
  • 2.3. Most active Drug Delivery dealmakers
  • 2.4. Drug Delivery partnering by deal type
  • 2.5. Drug Delivery partnering by therapy area
  • 2.6. Deal terms for Drug Delivery partnering
    • 2.6.1. Drug Delivery partnering headline values
    • 2.6.2. Drug Delivery deal upfront payments7
    • 2.6.3. Drug Delivery deal milestone payments
    • 2.6.4. Drug Delivery royalty rates

Chapter 3 - Leading Drug Delivery deals

  • 3.1. Introduction
  • 3.2. Top Drug Delivery deals by value

Chapter 4 - Most active Drug Delivery dealmakers

  • 4.1. Introduction
  • 4.2. Most active Drug Delivery dealmakers
  • 4.3. Most active Drug Delivery partnering company profiles

Chapter 5 - Drug Delivery contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Drug Delivery contracts dealmaking directory

Chapter 6 - Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Drug Delivery deals by company A-Z

Appendix 2 - Drug Delivery deals by stage of development

  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation

Appendix 3 - Drug Delivery deals by deal type

  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty

Appendix 4 - Drug Delivery deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Drug Delivery partnering since 2010
  • Figure 2: Active Drug Delivery dealmaking activity- 2010 to 2016
  • Figure 3: Drug Delivery partnering by deal type since 2010
  • Figure 4: Drug Delivery partnering by disease type since 2010
  • Figure 5: Drug Delivery deals with a headline value
  • Figure 6: Drug Delivery deals with an upfront value
  • Figure 7: Drug Delivery deals with a milestone value
  • Figure 8: Drug Delivery deals with a royalty rate value
  • Figure 9: Top Drug Delivery deals by value since 2010
  • Figure 10: Most active Drug Delivery dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top